An implant for insertion into a punctum of a patient comprises a body. The body has a distal end, a proximal end, and an axis therebetween. The distal end of the body is insertable distally through the punctum into the canalicular lumen. The body comprises a therapeutic agent included within an agent matrix drug core. Exposure of the agent matrix to the tear fluid effects an effective therapeutic agent release into the tear fluid over a sustained period. The body has a sheath disposed over the agent matrix to inhibit release of the agent away from the proximal end. The body also has an outer surface configured to engage luminal wall tissues so as to inhibit expulsion when disposed therein. In specific embodiments, the agent matrix comprises a non-bioabsorbable polymer, for example silicone in a non-homogenous mixture with the agent.

The present invention corresponds to the composition of a unique formula to be used as pre-dipping and post-dipping in robot milking in order to control mastitis in bovines. The composition comprises at least one organic zinc salt, water soluble and with biocidal properties, where the concentration of zinc ions is in the range of 5,000 to 60,000 ppm. The salts with biocidal properties were selected for having a functional group similar to proteins. Organic zinc salts are degradable, less irritating to the cow's teat, improve the skin condition, have an anti-inflammatory effect, accelerate wound healing processes and eliminate bacteria and fungi. The organic zinc salts selected for this invention were the following: gluconate, lactate, glycinate, lysinate, citrate trihydrate, picolinate, and acetate. Zinc sulfate monohydrate can be optionally added, but in low concentration, less than 1.5% of the final product. The viscosity of the spray composition should be in the range of 3 to 5 centipoise (cP), at room temperature. Finally, and very importantly, the composition has no corrosive activity on metals and non-metals, such as stainless steel, carbon steel, computer cards and other components found in bovine milking robots.

Compositions containing an amorphous biologically active ingredient and porous particles materials are disclosed. Methods of making and using the compositions to provide topical and/or dermal compositions for the treatment of humans and animals are also disclosed.

The invention relates to a dosage projectile for administering an active agent to an animal, the projectile configured to contain an active agent and having a frangible shell adapted to fragment on impact with an animal to deliver the active agent to the animal and produce a plurality of shell fragments associated with the animal after impact to provide a visible mark on the animal.

The invention relates to a pharmaceutical composition comprising: at least one antiparasitic active ingredient for providing the pharmacological therapeutic effect; an agent having bio-adhesive properties that helps to reduce the motility and reproduction of the parasites, increasing the period of time for which the product remains on the skin of the animals; an agent having permeation- or absorption-promoting properties that contributes to increasing the cutaneous permeability of the active ingredient; a surfactant agent that is absorbed in an oil-water interface, and as a result, the molecules of said surfactant agent form a kind of bridge between the polar phase (water) and the non-polar phase (oil), thereby making the transition between both phases less abrupt; an oil which will form the oily phase of the emulsion, and which will incorporate the active ingredient; and a neutralizing agent.

The present invention relates generally to compositions with a health benefit. In particular, the invention relates to bacterial preparations of Lactobacillus plantarum CNCM I-4026 (NCC 2936). An aspect of the invention is a composition for use in the treatment or prevention of skin infections comprising a bacterial preparation of Lactobacillus plantarum CNCM I-4026. A further aspect is a cosmetic composition comprising a bacterial preparation of Lactobacillus plantarum CNCM I-4026.

Histatins are used to treat ocular surface diseases such as dry eye. For example, histatins are included in eye drops, eye gels, ointment, glue, or embedded in (polymer) contact lenses. In some embodiments, peptide fragments from at least two different histatins are used. In some other embodiments, an additional therapeutic (nonhistatin) agent is used in combination with the histatins. In some embodiments, histatin 5 or fragments of histatin 5 are used in combination with an additional therapeutic (non histatin) agent. Histatins may alternatively be included as preservatives in ophthalmic preparations.

A process of making a composition of matter with emollient properties. The composition takes the physical form of an oil base homogenized into water, making it suitable for dispensation in large quantities with a spray bottle or a continuous flow. Preparation begins with refinement of MCT coconut oil to remove lauric acid. The coconut oil is mixed with arnica oil, castor oil, and CBD oil to form the oil base. Ideal proportions for the oil base are approximately 1:4:1:4 arnica:castor:CBD:coconut. The oil base is then heated and homogenized into alkaline water by blending. Ideal parameters are approximately 11.5 pH water, a ratio of approximately 7:93 oil:water, and ten minutes of blending. Suitable variations on the ideal parameters are disclosed below.

A method of treating a disease state or condition in mammals other than humans via topical brainstem afferent stimulation therapy via the administration of a cannabinoid drug(s) to the back of the neck region and/or spine to provide regional neuro-affective therapy is disclosed. In certain preferred embodiments, the cannabinoid drug(s) are not psychoactive or substantially not psychoactive. In certain embodiments, the cannabinoid drug(s) are incorporated into a pharmaceutically acceptable topical carrier, e.g., a cream or mousse. In certain preferred embodiments, the cannabinoid drug(s) comprises cannabidiol.

A teat protective pack material for coating teats of lactating livestock to prevent mastitis is disclosed, the teat protective pack material including a polymer latex and a coagulant for coagulating the polymer latex to form a film. The teat protective pack material optionally includes a surfactant, a mold-releasing agent, a water-soluble polymer, water and/or a water-soluble solvent, an antifreezing agent, etc. if required. The teat protective pack material, may have excellent adhesiveness, elasticity, abrasion resistance, durability, aging resistance, oil resistance, weatherability, breast shape followability, etc. The teat protective pack material may be capable of immediately coating the whole teat and thus preventing adhesion of teat packs adjacent to each other, and, when milking again or in case of emergency, may be able to be quickly removed without using any additional facility, material, etc.